ALIMTA 100 MG
PEMETREXED (PEMETREXED DISODIUM) : 100 MG · DIN 02306433 · ELI LILLY CANADA INC
Health Canada status: CANCELLED POST MARKET
What is ALIMTA?
ALIMTA 100 MG contains PEMETREXED (PEMETREXED DISODIUM) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02306433, held by ELI LILLY CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 29-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALIMTA used for?
Malignant pleural mesothelioma (with cisplatin); Initial treatment of nonsquamous NSCLC (with cisplatin); Maintenance or second-line treatment of nonsquamous NSCLC (monotherapy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02306433 |
|---|---|
| Brand name | ALIMTA |
| Generic / active ingredient | PEMETREXED (PEMETREXED DISODIUM) : 100 MG |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 100 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01BA04 PEMETREXED |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 29-Jan-2026 |
| Original market date | 2009-01-09 00:00:00 |
How is it administered?
500 mg/m2 as an IV infusion over 10 minutes every 21 days. Must supplement with folic acid, vitamin B12, and dexamethasone. Cisplatin is co-administered for certain indications.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C.
How is it supplied?
100 mg or 500 mg pemetrexed per vial.
Contraindications
Hypersensitivity to pemetrexed or any ingredient in the formulation; concomitant yellow fever vaccine.
Warnings and precautions
Should be administered under supervision of a physician experienced in cancer chemotherapy. Bone marrow suppression is the dose-limiting toxicity. Risk of hepatotoxicity and renal failure.
Is PEMETREXED in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BA04 PEMETREXED. 14 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528746 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02459434 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02517639 |
| PEMETREXED DISODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02438674 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528754 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02438682 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02394227 |
| PEMETREXED DISODIUM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02517647 |
| PEMETREXED FOR INJECTION | 25 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02515423 |
| PEMETREXED FOR INJECTION, USP | 100 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02463083 |
Who else supplies PEMETREXED worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PEMETREXED appears in 161 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.